Table 3 The main features of the included studies on miR-29 in the prognosis of CRC
First author | Year | Country | Ethnicity | M/F | N | Age | TNM stage | Sample source | miRNA | Methods | Endpoints | Follow-up time (months) | Hazard ratio | Scores |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Brenner [42] | 2011 | Israel | Asian | 34/25 | 59 | 78 | II | Tissue | miR-29a | RT-PCR | DFS | NA | 0.194 (0.063–0.597) | 7 |
Tang [37] | 2014 | China | Asian | 46/39 | 85 | 60 | I-IV | Tissue | miR-29a | RT-PCR | OS | 40 | 1.556 (1.066–2.282) | 9 |
Inoue [38] | 2014 | Japan | Asian | 153/92 | 245 | NA | I-IV | Tissue | miR-29b | RT-PCR | OS | 54 | 0.459 (0.240–0.850) | 8 |
Inoue [38] | 2014 | Japan | Asian | 153/92 | 245 | NA | I-IV | Tissue | miR-29b | RT-PCR | DFS | 54 | 0.452 (0.222–0.915) | 7 |
Basati [30] | 2015 | Iran | Asian | 30/25 | 55 | 58.5 | I-IV | Serum | miR-29b | RT-PCR | OS | 40 | 0.142 (0.029–0.342) | 7 |
Yuan [40] | 2017 | China | Asian | 81/63 | 144 | 56.1 | I-IV | Plasma | miR-29a | RT-PCR | RFS | NA | 2.610 (1.340–5.070) | 7 |
Ulivi [39] | 2018 | Italy | Caucasian | 35/17 | 52 | 65 | I-IV | Plasma | miR-29b | RT-PCR | OS | NA | 0.872 (0.753–0.991) | 8 |
Ulivi [39] | 2018 | Italy | Caucasian | 35/17 | 52 | 65 | I-IV | Plasma | miR-29b | RT-PCR | PFS | NA | 0.854 (0.728–0.997) | 8 |